Plasma Cell Leukemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Conditions
Brief summary
This pilot clinical trial studies whether using high throughput drug sensitivity and genomics data is feasible in developing individualized treatment in patients with multiple myeloma or plasma cell leukemia that has come back or does not respond to treatment. High throughput screen tests many different drugs that kill multiple myeloma cells in individual chambers at the same time. Matching a drug or drug combination to a patient using high throughput screen and genetic information may improve the ability to help patients by choosing drugs that work well for their disease.
Detailed description
OUTLINE: Patients undergo collection of bone marrow aspirate and blood for high-throughput drug sensitivity assay and mutational analysis using next generation sequencing. Patients and their treating physicians receive the results of the tests. Treatment decisions are then made by the patients and their treating physicians. After completion of study, patients are followed up every 3 months for 2 years.
Interventions
PROCEDUREBiospecimen Collection
Undergo collection of bone marrow aspirate and blood
DEVICEHigh Throughput Screening
Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay
OTHERLaboratory Biomarker Analysis
Correlative studies
Sponsors
University of Washington
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of multiple myeloma or plasma cell leukemia with documented relapsed or refractory disease according to International Myeloma Working Group (IMWG) criteria, in any one of the following categories: * 3 prior lines of therapy including an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI) * Less than a very good partial response (VGPR) to initial therapy * Early relapse (\< 12 months) after autologous hematopoietic cell transplant (HCT) or after 1st line of therapy * Collection of a bone marrow, fluid or tissue sample that is expected to have enough cells to run the assay * Measurable disease defined by one of the following: * Serum monoclonal protein \>= 0.5 g/dL by serum protein electrophoresis (SPEP) * \>= 200 mg/monoclonal protein in urine on 24 hr urine protein electrophoresis (UPEP) * Involved serum free light chain (FLC) \>= 10 mg/dL and abnormal involved:uninvolved ratio * Plasma cytomas that are palpable per exam or measurable per standard radiologic review * Circulating plasma cells \>= 2,000 if diagnosis of plasma cell leukemia * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3 * Female patients of child bearing potential and non-vasectomized male patients agree to practice appropriate methods of birth control * Ability to understand purpose and risks of the study and provide signed and dated informed consent, and authorization to use protected health information * Expected survival is \> 100 days * Adequate organ function as determined by the investigator
Exclusion criteria
* Mucosal or internal bleeding, or platelet transfusion refractory * Any medical conditions that would impose excessive risk to the patient, or would adversely affect his/her participation in the study * Known active infection requiring antibiotics within 7 days of initiation of study treatment, unless considered controlled in the opinion of the investigator * Other malignancy with life expectancy \< 1 year due to the other malignancy * Pregnant or breast feeding women * Serious psychiatric illness, alcoholism, or drug addiction * Human immunodeficiency virus (HIV), or active hepatitis B or C infection * Previous treatments for multiple myeloma (MM) within 2 weeks of initiation of study treatment * Prior autologous or allogeneic stem cell transplantation (SCT) within 12 weeks of initiation of study treatment * Prior allogeneic hematopoietic cell transplantation (HCT) with active graft versus host disease (GVHD) on therapeutic dosing of immunosuppression or prednisone \> 20 mg daily equivalent * Prior major surgical procedure or radiation treatment within 2 weeks of initiation of study treatment (not including limited radiation used for palliation of bone pain)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Actionable Assay Response | Up to 21 days | The feasibility of this approach will be assessed in terms of obtaining an actionable response from the proposed assay in at least 50% of patients examined. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate to the Therapy Chosen After Performing the Assay | Up to 2 years | Will be assessed by the International Myeloma Working Group (IMWG) response criteria. The response among all patients who received the assay as well as among patients who obtained an actionable result from the assay will be estimated. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORDanai Dima, MD
Fred Hutch/University of Washington Cancer Consortium
Participant flow
Pre-assignment details
Of 55 screened participants, 40 met inclusion criteria and were enrolled.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 19 Participants |
| Age, Categorical Between 18 and 65 years | 21 Participants |
| Age, Continuous | 62.33 years STANDARD_DEVIATION 10.74 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 37 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Region of Enrollment United States | 40 participants |
| Sex: Female, Male Female | 18 Participants |
| Sex: Female, Male Male | 22 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 26 / 40 |
| other Total, other adverse events | 0 / 40 |
| serious Total, serious adverse events | 0 / 40 |
Outcome results
None listed